Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians--including, but not limited to, office managers, billing specialists, receptionists, and administrative staff--may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.

Venue

Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Courtyard by Marriott Philadelphia Downtown
21 N. Juniper St.
Philadelphia, PA

Saturday, November 17, 2018

  • Registration and Exhibits

    Coffee will be served.

  • Registration and Exhibits

    Coffee will be served.

  • Big News in Small Fiber Neuropathies

    During the past 10 years, small fiber neuropathy has become increasingly associated with a seemingly expanding number of medical conditions. This course will review the condition in general as well as the most recent advances in our understanding of its pathophysiology and how we can treat patients diagnosed with small fiber neuropathy.

    • UAN: 0530-0000-18-396-L01-P
    • AANP Rx Hours: 0.2

  • Big News in Small Fiber Neuropathies

    During the past 10 years, small fiber neuropathy has become increasingly associated with a seemingly expanding number of medical conditions. This course will review the condition in general as well as the most recent advances in our understanding of its pathophysiology and how we can treat patients diagnosed with small fiber neuropathy.

    • UAN: 0530-0000-18-396-L01-P
    • AANP Rx Hours: 0.2

  • Product, Disease Awareness, Medical Information Program*

    Charles Argoff, MD

    Breakfast will be served.

    Sponsored by Arbor Pharmaceuticals

  • Break & Exhibits

  • 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

    There is much controversy around many aspects of pain treatment, and compelling arguments have focused on both sides of the fence regarding appropriate opioid use and prescribing, legalization of marijuana, and the safety of cox-2 inhibitors. In all 3 cases, there are issues associated with strong positions, although the evidence, when put into practice, is less black and white. For each topic, we will evaluate current literature and debate the clinical, legal, and ethical controversies surrounding recent developments in pain management. Attendees will get a better understanding as presenters debate evidence based application of the cdc guidelines in various clinical settings, evaluate clinical and ethical concerns regarding marijuana for medicinal or recreational use, and take a critical look at the literature and its application when using cox-2 inhibitors for treating pain.

    • UAN: 0530-0000-18-031-L01-P
    • AANP Rx Hours: 0.0

  • Evidence-Based Approaches to Chronic Pain Management: Time to Reconsider the Benefit of Technophilism?

    Americans are obsessed with all that is technical, yet technologically-focused approaches to chronic pain management are not necessarily the most effective approaches. Despite their perceived promise, unimodal approaches such as medications, surgery, spinal cord stimulation, intrathecal opioid pumps, and various other interventional approaches are not necessarily the most effective ways to treat chronic pain. Primary care physicians, when overwhelmed by these patients, are apt to refer them either to interventionalists or surgeons prematurely, resulting in myriad unnecessary injections and surgeries--with iatrogenic complications associated with both. This presentation will emphasize the potential benefits of considering referral of patients with chronic pain to physiatrists--who are the pain specialists with the broadest armamentaria for treating the biopsychosocial complexities of these conditions.

    • UAN: 0530-0000-18-037-L01-P
    • AANP Rx Hours: 0.0

  • Faculty Q&A

  • Break & Exhibits

  • Product, Disease Awareness, Medical Information Program*

    Gerald Sacks, MD

    Lunch will be served. 
    Sponsored by Salix Pharmaceuticals

  • Lost in Translation: Making Sense of Clinical Treatment Guidelines

    Multiple clinical treatment guidelines have been published regarding headache and pain management. However, many have questioned the benefit of such clinical guidelines for the treatment of individual patients. This course will review key published treatment guidelines for migraine, interventional pain management, chronic opioid use, neuropathic pain, and chronic low back pain. The faculty will review the relevant guidelines and discuss their strengths and critical weaknesses when using such guidelines to actually treat people.

    • UAN: 0530-0000-18-040-L01-P
    • AANP Rx Hours: 0.0

  • Break & Exhibits

  • Product, Disease Awareness, Medical Information Program*

    Christopher G. Gharibo, MD

    Refreshments will be served.

    Sponsored by SCILEX

  • To Dream the Impossible Dream: Acute Pain Management for Patients on Buprenorphine

    With our current climate of opioid overuse and increasing opioid related deaths, alternatives to pure mu opioids are necessary. Buprenorphine, an important weapon in the arsenal for management of substance use disorder, is now rising in popularity as an opioid option for chronic pain. Evidence has demonstrated efficacy for various chronic pain conditions with less risk of adverse effects, such as the development of tolerance and respiratory depression. With increasing utilization, patients on chronic buprenorphine therapy are now more frequently being admitted to hospitals with severe acute pain due to surgery or trauma. A partial opioid agonist, buprenorphine has unique pharmacokinetic properties that differ from pure mu opioid agonists. Challenges with pain control can occur when acute pain treatment with a pure opioid is used in patients receiving buprenorphine due to its strong affinity to the mu receptor. This session will review the unique characteristics of buprenorphine and offer options for treatment of severe acute pain in patients receiving buprenorphine therapy.

    • UAN: 0530-0000-18-397-L01-P
    • AANP Rx Hours: 0.8

  • Reefer Madness Revisited

    Medical, and recreational, marijuana serve as sources of great confusion to patients and clinicians alike. A culture of "neuromysticism" around medical marijuana has arisen, leaving patients and clinicians alike confused regarding what constitutes "medical" marijuana. A part of this confusion is related to the poor quality of the available research on safety and efficacy, which are due, in part, to the restrictive scheduling of the drug. This lecture will focus on what we know, and what we don't know, about the efficacy and safety of medical cannabinoids. Specific recommendations regarding the safest and most effective use of medical marijuana as part of a pain management armamentarium will be provided.

    • UAN: 0530-0000-18-398-L01-P
    • AANP Rx Hours: 0.0

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!

More information >>

Schedule

Click on the day of the conference to see course descriptions, UAN numbers, and AANP pharmacology credits.

Saturday, November 17, 2018

Schedule (subject to change)

7:00a - 7:30a - Registration and Exhibits
Coffee will be served. 

7:30a - 8:30a - Big News in Small Fiber Neuropathies

UAN 0530-0000-18-396-L01-P

AANP Rx Hours 0.2

Course Description

During the past 10 years, small fiber neuropathy has become increasingly associated with a seemingly expanding number of medical conditions. This course will review the condition in general as well as the most recent advances in our understanding of its pathophysiology and how we can treat patients diagnosed with small fiber neuropathy.

Charles E. Argoff, MD, CPE

8:30a - 9:30a - Product, Disease Awareness, Medical Information Program*
Breakfast will be served.
Sponsored by Arbor Pharmaceuticals, Charles Argoff, MD

9:30a - 9:40a - Break & Exhibits

9:40a - 10:40a - 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

UAN 0530-0000-18-031-L01-P

AANP Rx Hours 0.0

Course Description

There is much controversy around many aspects of pain treatment, and compelling arguments have focused on both sides of the fence regarding appropriate opioid use and prescribing, legalization of marijuana, and the safety of cox-2 inhibitors. In all 3 cases, there are issues associated with strong positions, although the evidence, when put into practice, is less black and white. For each topic, we will evaluate current literature and debate the clinical, legal, and ethical controversies surrounding recent developments in pain management. Attendees will get a better understanding as presenters debate evidence based application of the cdc guidelines in various clinical settings, evaluate clinical and ethical concerns regarding marijuana for medicinal or recreational use, and take a critical look at the literature and its application when using cox-2 inhibitors for treating pain.

Tanya J. Uritsky, PharmD, BCPS

10:40a - 11:40a - Evidence-Based Approaches to Chronic Pain Management: Time to Reconsider the Benefit of Technophilism?

UAN 0530-0000-18-037-L01-P

AANP Rx Hours 0.0

Course Description

Americans are obsessed with all that is technical, yet technologically-focused approaches to chronic pain management are not necessarily the most effective approaches. Despite their perceived promise, unimodal approaches such as medications, surgery, spinal cord stimulation, intrathecal opioid pumps, and various other interventional approaches are not necessarily the most effective ways to treat chronic pain. Primary care physicians, when overwhelmed by these patients, are apt to refer them either to interventionalists or surgeons prematurely, resulting in myriad unnecessary injections and surgeries--with iatrogenic complications associated with both. This presentation will emphasize the potential benefits of considering referral of patients with chronic pain to physiatrists--who are the pain specialists with the broadest armamentaria for treating the biopsychosocial complexities of these conditions.

Michael E. Schatman, PhD, CPE, DASPE

11:40a - 12:00p - Faculty Q&A

12:00p - 12:10p - Break & Exhibits

12:10p - 1:10p - Product, Disease Awareness, Medical Information Program*
Lunch will be served.
Sponsored by Salix Pharmaceuticals, Gerald Sacks, MD

1:10p - 2:00p - Lost in Translation: Making Sense of Clinical Treatment Guidelines

UAN 0530-0000-18-040-L01-P

AANP Rx Hours 0.0

Course Description

Multiple clinical treatment guidelines have been published regarding headache and pain management. However, many have questioned the benefit of such clinical guidelines for the treatment of individual patients. This course will review key published treatment guidelines for migraine, interventional pain management, chronic opioid use, neuropathic pain, and chronic low back pain. The faculty will review the relevant guidelines and discuss their strengths and critical weaknesses when using such guidelines to actually treat people.

Charles E. Argoff, MD, CPE

2:00p - 2:10p - Break & Exhibits

2:10p - 3:00p - Product, Disease Awareness, Medical Information Program*
Refreshments will be served.
Sponsored by SCILEX, Christopher G. Gharibo, MD

3:00p - 3:50p - To Dream the Impossible Dream: Acute Pain Management for Patients on Buprenorphine

UAN 0530-0000-18-397-L01-P

AANP Rx Hours 0.8

Course Description

With our current climate of opioid overuse and increasing opioid related deaths, alternatives to pure mu opioids are necessary. Buprenorphine, an important weapon in the arsenal for management of substance use disorder, is now rising in popularity as an opioid option for chronic pain. Evidence has demonstrated efficacy for various chronic pain conditions with less risk of adverse effects, such as the development of tolerance and respiratory depression. With increasing utilization, patients on chronic buprenorphine therapy are now more frequently being admitted to hospitals with severe acute pain due to surgery or trauma. A partial opioid agonist, buprenorphine has unique pharmacokinetic properties that differ from pure mu opioid agonists. Challenges with pain control can occur when acute pain treatment with a pure opioid is used in patients receiving buprenorphine due to its strong affinity to the mu receptor. This session will review the unique characteristics of buprenorphine and offer options for treatment of severe acute pain in patients receiving buprenorphine therapy.

Tanya J. Uritsky, PharmD, BCPS

3:50p - 4:40pm - Reefer Madness Revisited

UAN 0530-0000-18-398-L01-P

AANP Rx Hours 0.0

Course Description

Medical, and recreational, marijuana serve as sources of great confusion to patients and clinicians alike. A culture of "neuromysticism" around medical marijuana has arisen, leaving patients and clinicians alike confused regarding what constitutes "medical" marijuana. A part of this confusion is related to the poor quality of the available research on safety and efficacy, which are due, in part, to the restrictive scheduling of the drug. This lecture will focus on what we know, and what we don't know, about the efficacy and safety of medical cannabinoids. Specific recommendations regarding the safest and most effective use of medical marijuana as part of a pain management armamentarium will be provided.

Michael E. Schatman, PhD, CPE, DASPE

 

*Not certified for credit.